Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| bryostatin 1, paclitaxel | PRKCE | Direct | 2 | ||||||||
| paclitaxel, bryostatin 1 | PRKCE | Direct | 1 | ||||||||
| midostaurin | PRKCE | Direct | yes | 0 | |||||||
| afatinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| dacomitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| erlotinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| gefitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| lazertinib and amivantamab | EGFR | SSL via EGFR | 1 | ||||||||
| osimertinib | EGFR | SSL via EGFR | yes | 1 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | RAF1 | SSL via RAF1 | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | RAF1 | SSL via RAF1 | 4 | ||||||||
| 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis | PDPK1 | SSL via PDPK1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | AKT1 | SSL via AKT1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | FYN | SSL via FYN | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | MAPK1 | SSL via MAPK1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | MAPK3 | SSL via MAPK3 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | RAF1 | SSL via RAF1 | 3 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | RAF1 | SSL via RAF1 | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | FYN | SSL via FYN | 2 | ||||||||
| bryostatin 1, paclitaxel | PRKCA | SSL via PRKCA | 2 | ||||||||
| carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy | PDPK1 | SSL via PDPK1 | 2 | ||||||||
| cpt- 11, cisplatin, celecoxib, radiation, surgery | PDPK1 | SSL via PDPK1 | 2 | ||||||||
| regorafenib | RAF1 | SSL via RAF1 | yes | 2 | |||||||
| regorafenib, laboratory biomarker analysis | RAF1 | SSL via RAF1 | 2 | ||||||||
| sorafenib, administered orally, ct/mri | RAF1 | SSL via RAF1 | 2 | ||||||||
| 7-hydroxystaurosporine, fluorouracil | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | FYN | SSL via FYN | 1 | ||||||||
| arsenic trioxide | AKT1 | SSL via AKT1 | 1 | ||||||||
| arsenic trioxide | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| arsenic trioxide | MAPK3 | SSL via MAPK3 | 1 | ||||||||
| arsenic trioxide, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| arsenic trioxide, radiation therapy | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| arsenic trioxide, radiation therapy | MAPK3 | SSL via MAPK3 | 1 | ||||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | MAPK3 | SSL via MAPK3 | 1 | ||||||||
| bevacizumab, dasatinib, placebo | FYN | SSL via FYN | 1 | ||||||||
| biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan | ATR | SSL via ATR | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, ulixertinib | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, ulixertinib | MAPK3 | SSL via MAPK3 | 1 | ||||||||
| botensilimab, balstilimab, chloroquine phosphate, celecoxib | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| capivasertib | AKT1 | SSL via AKT1 | 1 | ||||||||
| ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin | TP53 | SSL via TP53 | 1 | ||||||||
| celecoxib, cyclophosphamide, etoposide, thalidomide | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| celecoxib, isotretinoin, temozolomide, thalidomide | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| celecoxib, temozolomide, thalidomide, adjuvant therapy | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| ceralasertib, olaparib, durvalumab | ATR | SSL via ATR | 1 | ||||||||
| cisplatin, carboplatin, etoposide, durvalumab, ceralasertib | ATR | SSL via ATR | 1 | ||||||||
| cisplatin, pemetrexed disodium, sorafenib | RAF1 | SSL via RAF1 | 1 | ||||||||
| cytoreductive surgery, perifosine, temsirolimus | AKT1 | SSL via AKT1 | 1 | ||||||||
| cytoreductive surgery, perifosine, temsirolimus | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| cytoreductive surgery, perifosine, temsirolimus | PRKCA | SSL via PRKCA | 1 | ||||||||
| dabrafenib, trametinib | RAF1 | SSL via RAF1 | 1 | ||||||||
| dabrafenib, trametinib, carboplatin, vincristine | RAF1 | SSL via RAF1 | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | FYN | SSL via FYN | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | FYN | SSL via FYN | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | FYN | SSL via FYN | 1 | ||||||||
| dasatinib, mfolfox6 | FYN | SSL via FYN | 1 | ||||||||
| dasatinib, pharmacological study | FYN | SSL via FYN | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | FYN | SSL via FYN | 1 | ||||||||
| enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) | AKT1 | SSL via AKT1 | 1 | ||||||||
| enzastaurin, lomustine | AKT1 | SSL via AKT1 | 1 | ||||||||
| enzastaurin, temozolomide, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| eras-007, encorafenib, cetuximab, palbociclib | RAF1 | SSL via RAF1 | 1 | ||||||||
| everolimus, sorafenib | RAF1 | SSL via RAF1 | 1 | ||||||||
| gemcitabine, erlotinib, sorafenib | RAF1 | SSL via RAF1 | 1 | ||||||||
| gemcitabine, placebo, sorafenib | RAF1 | SSL via RAF1 | 1 | ||||||||
| gemcitabine, sorafenib, radiotherapy | RAF1 | SSL via RAF1 | 1 | ||||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | RAF1 | SSL via RAF1 | 1 | ||||||||
| genistein, erlotinib hydrochloride, gemcitabine hydrochloride | AKT1 | SSL via AKT1 | 1 | ||||||||
| laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery | AKT1 | SSL via AKT1 | 1 | ||||||||
| laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery | PRKCA | SSL via PRKCA | 1 | ||||||||
| lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil | RAF1 | SSL via RAF1 | 1 | ||||||||
| minocycline, placebo, questionnaires | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| oxaliplatin, sorafenib | RAF1 | SSL via RAF1 | 1 | ||||||||
| paclitaxel, bryostatin 1 | PRKCA | SSL via PRKCA | 1 | ||||||||
| perifosine | AKT1 | SSL via AKT1 | 1 | ||||||||
| perifosine | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| perifosine | PRKCA | SSL via PRKCA | 1 | ||||||||
| radiation therapy, temozolomide, sorafenib | RAF1 | SSL via RAF1 | 1 | ||||||||
| regorafenib, lomustine | RAF1 | SSL via RAF1 | 1 | ||||||||
| regorafenib, nivolumab, capeox, folfox regimen | RAF1 | SSL via RAF1 | 1 | ||||||||
| regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil | RAF1 | SSL via RAF1 | 1 | ||||||||
| regorafenib, temozolomide | RAF1 | SSL via RAF1 | 1 | ||||||||
| sorafenib | RAF1 | SSL via RAF1 | yes | 1 | |||||||
| sorafenib, erlotinb | RAF1 | SSL via RAF1 | 1 | ||||||||
| sorafenib, rad001 | RAF1 | SSL via RAF1 | 1 | ||||||||
| sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide | RAF1 | SSL via RAF1 | 1 | ||||||||
| tamoxifen, etoposide | PRKCA | SSL via PRKCA | 1 | ||||||||
| temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 | RAF1 | SSL via RAF1 | 1 | ||||||||
| topotecan hydrochloride, 7-hydroxystaurosporine | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| topotecan, sorafenib | RAF1 | SSL via RAF1 | 1 | ||||||||
| trc 105, sorafenib | RAF1 | SSL via RAF1 | 1 | ||||||||
| vemurafenib, sorafenib | RAF1 | SSL via RAF1 | 1 | ||||||||
| afatinib dimaleate | EGFR | SSL via EGFR | yes | 0 |